Evidence map›Paper›PMID 40003577›Full record

ArticleLife (Basel, Switzerland)2025

Assessment of Arteriovenous Fistula Maturation in Hemodialysis Patients with Persistently Positive Antiphospholipid Antibody: A Prospective Observational Cohort Study.

Maxime Taghavi, Lucas Jacobs, Saleh Kaysi, Yves Dernier, Edouard Cubilier, Louis Chebli, Marc Laureys, Frédéric Collart, Anne Demulder, Marie-Hélène Antoine and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06112821 (Arteriovenous Fistula Maturation in Hemodialysis Patients With or Without Positive Antiphospholipid Antibodies), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06112821 unknown statusnot on this map

Arteriovenous Fistula Maturation in Hemodialysis Patients With or Without Positive Antiphospholipid Antibodies : A Prospective Observational Cohort Study.

TypeobservationalSponsorBrugmann University HospitalRan2022 to 2024Enrolled100ConditionsChronic Kidney DiseasesArmsData collection in medical records, Blood sampling
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maxime TaghaviNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.ORCID 0000-0003-1442-9716
Lucas JacobsNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.ORCID 0000-0001-8148-0349
Saleh KaysiNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.
Yves DernierVascular Surgery Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.
Edouard CubilierNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.
Louis ChebliVascular Surgery Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.
Marc LaureysRadiology Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.ORCID 0009-0008-6590-8606
Frédéric CollartNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.ORCID 0000-0003-1673-5450
Anne DemulderLaboratory of Hematology and Hemostasis, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.ORCID 0000-0002-5198-8536
Marie-Hélène AntoineLaboratory of Experimental Nephrology, Faculty of Medicine, Université Libre de Bruxelles (ULB), Erasme Campus, 1070 Brussels, Belgium.ORCID 0000-0002-8600-1818
Joëlle NortierNephrology and Dialysis Department, Brugmann University Hospital, Université Libre de Bruxelles (ULB), 1020 Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArteriovenous fistula (AVF) is the preferred vascular access option for hemodialysis (HD). The latter requires a remodeling process called maturation that can take up to 3 months. Maturation failure is a frequent complication associated with significant morbidity. The prevalence of antiphospholipid antibody (aPL) positivity in HD patients is high and may result in thrombosis of the vascular access. Recently, aPL persistent positivity has been associated with AVF maturation failure in a retrospective study including 116 patients.

methodsWe are conducting an observational prospective cohort study aiming to evaluate this association. Included patients are planned for AVF creation, aged over 18 years old, and have an interpretable aPL assay confirmed at 12 weeks and without any other innate or acquired thrombophilia or inflammatory disease. Primary endpoints will be the evaluation of AVF maturation clinically and by ultrasound. Secondary endpoints will focus on clinical outcomes other than AVF maturation (i.e., primary patency, thrombosis or stenosis, bleeding and hemodialysis adequacy parameters).

conclusionsThis prospective observational cohort study aims to examine the possibly causative link between aPL persistent positivity and AVF maturation failure. This study was registered on ClinicalTrials.gov (ID number: NCT06112821).

Indexed as

antiphospholipid antibodiesarteriovenous fistulahemodialysismaturation

Identifiers

PMID40003577
PMCPMC11856552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.